February 6, 2014 | Israeli company Tiltan Pharma, which is developing a treatment for pancreatic cancer, has raised $1.5 million. The company will use the proceeds to complete its Phase II clinical trial of its metastatic pancreatic cancer treatment TL-118. Details about the source of the investment were not disclosed.
Related posts
Clean Energy Company That Mimics The Sun Raises $22M
February 02, 2023
Blood Test Offers Hope For Lung Cancer Patients
February 02, 2023
Israel Opens Its First Satellite Observatory
February 02, 2023
Cloud Data-Securing Startup Raises $30M
February 01, 2023
Facebook comments